ESG

Manic Panic's new Inter-Gel-Actic collection features a revolutionary gel formula designed to make vibrant, at-home hair color easier than ever before.

A global alliance alleges a "drip-drip genocide" of Hindus in Bangladesh, citing a drastic population collapse and escalating violence under recent turmoil.

Acurx Pharmaceuticals preps for pivotal Phase 3 trials for its novel C. diff antibiotic, Ibezapolstat, with global regulatory alignment in place.

Amid unprecedented supply chain chaos, Westrock Coffee met its 100% responsible sourcing goal. Here's how they did it and what it means for the industry.

After a brutal 2024 and a massive strategy shift, all eyes are on Stellantis's 2025 earnings. Will the numbers justify its painful pivot away from EVs?

Zemcelpro® gains key reimbursement status, offering immediate hope and access for German patients with limited options and paving a new path for cell therapy.

AI biotech firm Juvenescence hires a top CTO and moves into Abu Dhabi, aiming to unlock anti-aging secrets with massive genomic data and AI.

A landmark trial shows Retevmo significantly cuts cancer recurrence in early-stage patients, pushing for a new standard of care and early genetic testing.

New research reveals the UK's booming sauna culture is more than just heat; it's a powerful social tool that could be prescribed to combat loneliness.

Three top Marriott resorts in Phuket & Khao Lak are wooing families with a new 'Kids Eat Free' program, promising big savings and diverse holiday experiences.

Dr. Batra's launches XODerma, a high-tech exosome skin therapy in Dubai, blending homeopathy with cellular science. But does the hype outpace regulation?

French firm Policloud unveils a bold strategy for 1,000 green, sovereign micro-data centers by 2030, challenging the dominance of tech hyperscalers.

The global energy giant unveils a new strategic roadmap and lubricants in India, betting on its distributor network to navigate a competitive, evolving market.

With strategic hires and a new focus, Cahill is building a transatlantic team to capture the booming data center and real estate finance market.

Indian startup DUSQ lands ₹24 crore to challenge global sleep-tech giants with a novel platform that promises to restore sleep, not just score it.

A landmark trial for Roche’s Gazyva shows unprecedented success in treating primary membranous nephropathy, offering hope of preventing kidney failure.

As the 139th Canton Fair opens pre-registration, record-breaking attendance and digital upgrades signal a robust outlook for global trade in 2026.

The veteran-founded coffee brand is on the clock after its stock price fell below $1.00, triggering a six-month window to brew a market turnaround.

Disc Medicine's promising EPP drug hits a major roadblock as the FDA seeks more data, delaying hope for patients and setting up a high-stakes trial.

A new device blending light and sound therapy aims to give athletes a mental edge. But as BrainTap Sports enters the arena, can it prove its mettle?